Drug intelligence / Profile preview

CGN-1

Development stage: Unknown
Lead developer: Capsigen
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Intravenous, Intrathecal

Overview

CGN-1 is an engineered, neurotropic adeno-associated virus (AAV) capsid developed by Capsigen using its proprietary TRADE (Targeted Remote AAV Determinant Engineering) platform. It serves as a proof-of-concept case study demonstrating the platform's ability to create vectors with enhanced tropism for the central nervous system (CNS). While CGN-1 itself is not a clinical drug candidate, the technology behind it is utilized in strategic collaborations, such as with Biogen, to develop gene therapies for CNS and neuromuscular indications. The capsid is designed to enable more efficient and targeted delivery of genetic payloads to brain and spinal cord tissues compared to naturally occurring AAV serotypes.

Beyond the preview

Go deeper on CGN-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGN-1.

Explore the full profile